Extended Data Fig. 2: Characterization of immune dynamics in the TME following anti-CTLA-4 treatments. | Nature Cancer

Extended Data Fig. 2: Characterization of immune dynamics in the TME following anti-CTLA-4 treatments.

From: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling

Extended Data Fig. 2

(a) Principle component analysis (PCA) of the relative abundance of each cell type in each sample, or the mean gene expression of genes with UMI > 2 in cells > 5 in each sample. Performed separately on lymphoid and myeloid cells. Pointes are samples color coded for treatment arm. Dashed line separates control and anti-CTLA-4 m1 from anti-CTLA-4 m2a. (b) Comparison of the fractions of the indicated lymphoid cell types in individual mice in each treatment group. n = 3, 2 and 3 biologically independent samples for Ctrl, m1 and m2a groups respectively were used for statistical analysis. (c) Comparison of the fractions of the indicated myeloid cell types in individual mice in each treatment group. n = 5, 3 and 5 biologically independent samples for Ctrl, m1 and m2a groups respectively were used for statistical analysis. Bars represent mean ± SE of mice per treatment arm. Two-tailed Student’s t test was used.

Back to article page